Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
about
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsOritavancin for acute bacterial skin and skin structure infections.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Novel antibiotics: are we still in the pre-post-antibiotic era?Oritavancin: A Long-Half-Life Lipoglycopeptide.The times they are a-changin': new antibacterials for skin and skin structure infections.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-resistant Enterococcus faecium Isolates in an In Vitro PK/PD Model of Infection.Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.Inhibition of d-Ala incorporation into wall teichoic acid in Staphylococcus aureus by desleucyl-oritavancin.
P2860
Q26772897-5C639390-E863-4618-9040-E44E07373EB2Q36086423-57498300-1143-4E3C-AB73-BA0FA02A63A8Q37287661-C2AD3317-82BC-4990-B55B-38F48BE6700FQ38233471-8708156C-6D4E-4230-89EE-1DBEAA7F86F4Q38363223-8A1A08F6-1D9E-40F7-B239-D4C30C5CAEFFQ38434265-A0F986ED-B2F5-4529-AC3D-CCF586127CABQ38438503-8912A285-8E9C-4489-BA27-D678C38AC25BQ38606618-7AB602F0-4EC3-4578-BA4B-0A3A79A60F74Q38615330-E475E640-D6AD-4EEB-BF9B-D18C13469211Q38646905-DF5511D0-868E-4B53-BC9E-6DB7CDEF6855Q39031976-E5A3D2BF-C85E-4A2D-979D-CB93649F6F12Q40103272-97F4346F-8D5C-43E9-B5FE-DE96876C065CQ40187951-34A6BA96-A913-4CA2-8D0F-82D7AF59F8D0Q41493636-9056CFEC-1FC6-4B70-8416-CAB74846894DQ41810303-C78ED975-8B0F-49F5-9B75-26A4964F34A0Q48357083-AE66562B-744A-427E-9F1E-A58AE01C916FQ50192704-9F980B80-0371-417B-95C4-AE894955B6F7Q52680606-6CB6D4D9-7B99-48B0-961E-4A1A8A003CEBQ52871978-C945E78E-7063-47FF-AA35-AA390D67D4CD
P2860
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@en
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@nl
type
label
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@en
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@nl
prefLabel
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@en
Pharmacodynamics of a simulate ...... aphylococcus aureus infection.
@nl
P2093
P2860
P356
P1476
Pharmacodynamics of a simulate ...... taphylococcus aureus infection
@en
P2093
Adam Belley
Francis F Arhin
Ingrid Sarmiento
Warren Rose
P2860
P304
P356
10.1128/AAC.01428-12
P407
P50
P577
2012-10-22T00:00:00Z